
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with increasing global incidence and prevalence. Despite various available treatment options, positioning new drugs remains a clinical challenge due to the absence of specific guidelines. UC management is evolving toward a more personalized approach tailored to individual patient profiles. A treat-to-target strategy, focusing on objective parameters such as histological, ultrasonographic, and molecular markers alongside clinical, endoscopic, and biochemical targets, is becoming the preferred method for disease control. Additionally, dual-targeted therapy has emerged as a promising strategy for patients who do not achieve remission with standard treatments. This review provides an overview of current and emerging strategies to optimize UC management and improve patient outcomes.
Like
Save
Share